This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Veeva Systems (VEEV) Rides High on Commercial Cloud Platform
by Zacks Equity Research
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.
Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition
by Zacks Equity Research
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
PerkinElmer Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
PerkinElmer's (PKI) portfolio has not only boosted the company's organic growth trajectory but has also helped boost market share worldwide. Solid estimate revision trend boosts investor confidence.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
Genomic Health's Cost Pressure Mounts, Cancer Tests Strong
by Zacks Equity Research
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.